Lorlatinib Is Active in Drug-Resistant NSCLC.

Article Details

Citation
Copy to clipboard

Authors unspecified

Lorlatinib Is Active in Drug-Resistant NSCLC.

Cancer Discov. 2016 Aug;6(8):OF1. doi: 10.1158/2159-8290.CD-NB2016-087. Epub 2016 Jul 8.

PubMed ID
27401797 [ View in PubMed
]
Abstract

Data from a phase I study indicate that the investigational ALK inhibitor lorlatinib is active in patients with ALK- or ROS1-positive non-small cell lung cancer, including those with brain metastases. Objective responses were seen among patients with known ALK resistance mutations who had relapsed following treatment with other tyrosine kinase inhibitors.

DrugBank Data that Cites this Article

Drugs